EP1587943A1 - Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme - Google Patents

Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme

Info

Publication number
EP1587943A1
EP1587943A1 EP03813309A EP03813309A EP1587943A1 EP 1587943 A1 EP1587943 A1 EP 1587943A1 EP 03813309 A EP03813309 A EP 03813309A EP 03813309 A EP03813309 A EP 03813309A EP 1587943 A1 EP1587943 A1 EP 1587943A1
Authority
EP
European Patent Office
Prior art keywords
alanine
ester
dimethyl phenyl
enzyme
counter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813309A
Other languages
German (de)
French (fr)
Inventor
Oh-Jin Park
Sang Who Lee
Tae-Yoon Park
Sang Hyun Lee
Won-Kyo Joung
Byoung-Woo Suh
Jeung-Soon Choi
Goonho Joe
Jae Ho Cheong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of EP1587943A1 publication Critical patent/EP1587943A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/06Alanine; Leucine; Isoleucine; Serine; Homoserine

Definitions

  • the present invention relates to methods for stereospecifically preparing (R)- or (S)-N-
  • (2,6-dimethyl phenyl) alanine and counter ester compounds thereto using enzyme more specifically, methods of comprising reacting an enzyme having hydrolytic activity specific to one kind of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine esters ((R)-enantiomer and (S)- enantiomer) with the racemic mixture above to obtain (R)- or (S)-N-(2,6-dimethyl phenyl) alanine by optical resolution, or extracting (S)- or (R)-N-(2,6-dimethyl phenyl) alanine ester as an unreacted compound from a reaction mixture using solvent, or esterifying a certain alanine enantiomer separated by the optical resolution with alcohol to synthesize (S)- or (R)-N-(2,6- dimethyl phenyl) -danine ester.
  • Racemic (R), (S)-N-(2,6-dime1hyl phenyl) alanine and their ester compounds are useful as precursors for the synthesis of Metalaxyl, Benalaxyl, Furalaxyl, etc. having antifungal activity.
  • the antifungal activity of these compounds is generally resides with the (R)- enantiomer.
  • (R)-N-(2,6-dimethyl phenyl) alanine methyl ester can also be applied to the chiral form of Benalaxyl, Furalaxyl, etc.; however, the required optical purity for Metalaxyl-M is more than 95% ee.
  • racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine of the present invention no attempts using any enzymes for the optical resolution thereof have been made.
  • the existing optical resolutions using enzymes have been limited to the synthesis of aryloxypropionic acid as a precursor for crop-based herbicide and the synthesis of arylpropionic acid as a precursor for profen-based antiinflamatory agent.
  • the inventors of the present invention have carried out extensive investigations and thereby determined that when the racemic mixture of (R), (S)-N-(2,6-dirnethyl phenyl) alanine ester is reacted under room temperature and atmospheric pressure with an enzyme hydrolysizing only one of both enantiomers in the racemic mixture, (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and its counter ester can be prepared at high optical purity (> 96-99% ee).
  • the present invention is achieved based upon this finding.
  • the object of the present invention is to provide a method of economicaUy preparing (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester at high optical purity by optical resolution using enzyme.
  • the method of preparing (R)- or (S)-N- (2,6-dimethyl phenyl) alanine comprises steps of,
  • R is selected from the group consisting of unsubstituted or substituted and linear or branched C ⁇ - 8 alkyl or alkenyl, unsubstituted or substituted C 3 -C 6 cycloalkyl, unsubstituted or substituted aryl alkyl, and unsubstituted or substituted heteroaryl alkyl,
  • R in Formula 1 includes, but is not limited to, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, 2-pentyl, 3-methyl-l-butyl, 2-ethyl-l-hexyl, 2-chloroethyl, 2- bromoethyl, 3-chloropropyl, 3-bromopropyl, 2 ⁇ -dichloroethyl, l-chloro-2-propyl, oleyl, cyclohexyl, 1-cyclopropylmethyl, aUyl, phenyl, benzyl, propargyl, 2-phenoxy-l -ethyl, 2,4- dichlorobenzyl, methoxyethyl, ethoxyethyl, 1-thioethoxyethyl, and the like.
  • N-(2,6-dimethyl phenyl) -danine ester comprises the steps of,
  • step (B') may be replaced with the following step (B"):
  • racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester is used to express the racemic n ixture of (R)-N-(2,6-dimethyl phenyl) alanine ester and (S)-N-(2,6-dimethyl phenyl) alanine ester.
  • enantiomer is used to express one of a pair of molecular entities which are mirror images of each other and non-superimposable.
  • enantiomer is employed to sometimes express an enantiomeric alanine and sometimes express an enantiomeric alanine ester, depending upon contexts in this disclosure.
  • counter is used to express the corresponding ester of a complementary enantiomeric alanine to a certain enantiomeric alanine; i.e., the counter ester to (R)-N-(2,6- dimethyl phenyl) alanine means (S)-N-(2,6-dimethyl phenyl) alanine ester, and the counter ester to (S)-N-(2,6-dimethyl phenyl) alanine means (T)-N-(2,6-dimethyl phenyl) alanine ester.
  • the term "(R)-N-(2,6-dimethyl phenyl) alanine” is sometimes abbreviated as “(R)-form alanine” and the term “(S)-N-(2,6-dimethyl phenyl) alanine” is sometimes abbreviated as “(S)-form alanine.”
  • the term “(R)-N-(2,6- dimethyl phenyl) alanine ester” is sometimes abbreviated as “(R)-form ester” and the term “(S)- N-(2,6-dimethyl phenyl) alanine ester” is sometimes abbreviated as "(S)-form ester.”
  • the term “(R)-form enantiomer” or “(S)-form enantiomer” is used and its meaning, i.e., whether it is used to express (R)-form alanine or (R)-form alanine
  • racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester to which the optical resolution is carried out according to the present invention, are well known in the art to which the present invention pertains.
  • the racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester can be readily synthesized by reaction of 2-bromopropionic acid ester and 2,6-dimethylaniline.
  • the present invention uses an enzyme which enantioselectively hydrolyzes only one of (R)-form enantiomer [(R)-N-(2,6-dimethyl phenyl) alanine ester] and (S)-form enantiomer [(S)-N-(2,6-dimethyl phenyl) alanine ester] (hereinafter, sometimes referred to as "specific hydrolysis enzyme”), thereby allowing a particular enantiomer to be readily synthesized by a simple and inexpensive process.
  • step (A) of the method for preparation of (R)- or (S)-N-(2,6-dimethyl phenyl) alanine the racemic ester mixture is dissolved in an aqueous solution or a mixed solution consisting of water and a small amount of organic solvent and then reacted with a specific hydrolysis enzyme at a uniform temperature and pH.
  • Isolation of the hydrolyzed enantiomer from the reaction mixture in the step (B) can be achieved in different ways, depending upon a reaction system.
  • an unhydrolyzed ester compound ((R)- or (S)-form ester) can be extracted using organic solvents.
  • an organic layer containing an unhydrolyzed ester compound can be readily partitioned to obtain an aqueous layer containing newly synthesized alanine because the unhydrolyzed ester compound tends to be soluble in organic solvents.
  • (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester was also ascertained to have a very high optical purity (> 96 - 99% ee), which was separated in the unreacted form from the reaction mixture in the step (B'), or synthesized by esterification of the synthesized (R)- or (S)-N-(2,6-dimethyl phenyl) alanine with the alcohol in the step (B").
  • R in Formula 1 is desirably selected from the group consisting of allyl, 2-chloroethyl, melhoxyethyl and ethoxyethyl because these groups can aUow a short reaction time and increased optical purity.
  • the kinds of specific hydrolysis enzymes are not particularly limited so long as they can enantioselectively hydrolyze only one of (R)-form ester and (S)-form ester, but are preferably selected from Upases, proteases and esterases derived from microorganisms, animals or plants.
  • the specific hydrolysis enzyme is one or more selected from the group consisting of Lipase AK from Pseudomonas, Toyobo Immobilized lipase, Lipoprotein
  • Lipase PS and AH from Burkhoderia
  • Lipase QLM from Alcaligenes
  • Lipase OF from Candida
  • Selectivity to (R)-form and (S)-form enantiomers is determined by the kind of enzymes used in the hydrolysis reaction. Enzyme may be applied to the reaction system in the form of powder or aqueous solution. In some embodiments, a support-immobilized enzyme can be employed to simptify catalyst recovery for reuse. Such immobilization methods, e.g., attaching enzymes onto polymer support or inorganic support such as ceUte, are well known to those skilled in the art, and the detailed description thereof is therefore omitted.
  • the effective amount of enzyme depends upon the reaction parameters, for example, the reaction temperature, pH, concentration, reaction time, etc., its addition amount may be variably determined.
  • the effective amount of enzyme is preferably in the range of 0.1 - 100% by weight based upon the weight of substrate (racemic ester mixture). If the amount of enzyme used in the reaction is below the rninimum effective amount, the reaction time may be undesirably extended, and if the amount of enzyme is above a certain maximum effective value, the cost of the process is undesirably increased by the use of excessive enzyme and more extensive separation processes.
  • reaction conditions are not particularly limited but, for optimization of the enzymatic reaction, are preferably in the range of pH 3 - 12 and temperature 0 - 60°C, more preferably 30 - 50°C.
  • the hydrolysis reaction of step (A) may be carried out in an aqueous solution, or a mixed solution containing a small amount of organic solvent so as to enhance the solubility of substrate and reduce the inhibition of enzyme activity by reaction products.
  • the concentration of substrate used in the enzymatic reaction may also be varied depending upon various reaction parameters. Preferably, it is in the range of 500 mM - 1M for optimization of the enzymatic reaction but may be beyond 1 M in some cases.
  • ester compounds of the racemic mixture may not be weU dissolved in an aqueous solution described in the initial procedure, but some ester compounds dissolved in the aqueous solution contact and react with the enzyme.
  • a reaction system consisting of a smaU amount of water and a large amount of organic solvent may be used.
  • organic solvent used in the enzymatic reaction examples include, but are not limited to, hydrophilic solvents such as acetone, acetonitrile, alcohol, etc. and hydrophobic solvents such as isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc.
  • hydrophilic solvents such as acetone, acetonitrile, alcohol, etc.
  • hydrophobic solvents such as isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc.
  • a two-phase solvent consisting of hydrophiUc and hydrophobic solvents can also be employed.
  • organic solvent used in the extraction of step (B) or (B') include, but are not limited to, ethyl acetate, isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc. and the mixture of two or more thereof.
  • the esterification reaction in the step (B") is not particularly limited so long as it can be accomplished by reaction between the carboxyl group of (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and alcohol to give the desired (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester, which can be easily achieved by those skilled in the art, thus the description thereof is omitted in this disclosure.
  • EXAMPLE 1 Enzyme screens for optical resolution of racemic (R ⁇ (S>N-(2,6-dimethyl phenyl 1 ) alanine methyl ester
  • the kinds of enzymes used and the conversion rates of the racemic mixture are Usted in TABLE 1 below.
  • enzymes showing a conversion rate of around 50% after the lapse of a certain reaction time are potential candidates as highly enantioselective enzymes specific to (R)-form enantiomer or (S)-form enantiomer.
  • a variety of Upases can be considered as such candidates having a high enantioselectivity.
  • EXAMPLE 2 Enzyme screens for optical resolution of racemic (R . ( “ S -N-( " 2,6-dimethyl phenyl " ) alanine methyl ester
  • the kinds of enzymes used in experiment and the conversion rates of the racemic mixtures are Usted in TABLE 2 below.
  • EXAMPLE 3 Enzyme screens for optical resolution of racemic (R ⁇ (S -N-( " 2.6-dimethyl phenyl) alanine aUyl ester and racemic (R ( " S -N-(2.6-dimethyl phenvD alanine 2-chloroethyl ester
  • the analysis conditions are the foUowing:
  • conv. means conversion
  • ee p and e ⁇ mean the optical purity of product and the optical purity of reactant, respectively, as represented by the below formulas.
  • EXAMPLE 4 Optical resolution of (R fSVN-(Z6-dimethyl phenyl) alanine 2-chloroethyl ester by Lipase OF 20 mg of a racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine 2-chloroethyl ester was added to 1 ml of 1 M potassium phosphate buffer (pH 7.0) and 2 mg of Lipase OF was then added thereto, foUowed by shaking of the resulting mixture at 200 rpm and 35°C. The analysis of reaction was carried out in the same manner as in EXAMPLE 3.
  • Candida rugosa Lipase OF comprises mixed forms of a variety of isozymes, use of a specific isozyme among them is anticipated to be able to increase the optical purity of product.
  • 2-chloroethyl, 2-bromoethyl, allyl, methoxyethyl, ethoxyethyl ester and the like are particularly preferable as substrates for Lipase PS.
  • EXAMPLE 7 Optical resolution of racemic (R , (SVN-(2,6-dimethyl phenvD alanine ester varies with ratio of substrate and enzyme
  • the conversion rate increases as the amount of enzyme used increases. It can also be seen that the optimal amount of enzyme should be determined considering various parameters such as the kinds of enzyme and ester, conversion rate, optical purity and the like.
  • EXAMPLE 8 Optical resolution of racemic (R), (S -N-(2,6-dimethyl phenyl) alanine methyl ester by immobilized Lipase PS
  • Lipase PS 0.1 g was dissolved in 10 ml of 0.1 M calcium phosphate buffer (pH 7.0) and the resulting mixture was maintained at room temperature with being stirred, followed by filtering to remove insoluble materials. 4.5 ml of the filtrate solution was mixed with 1 M potassium phosphate (pH 7.0) and 30 mg of Sepabeads FP-EP16 ® (Resindion) was then added thereto, foUowed by stirring at room temperature overnight and subsequent filtering.
  • the bead- immobilized enzyme obtained thus was added to 1 ml of 0.1 M Tris buffer (pH 7), 10 mg of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine methyl ester was added thereto, then the reaction was run at 30°C for 17 hours while being shaken at 200 rpm.
  • the analysis of reaction was performed at the same manner as in EXAMPLE 3.
  • the immobilized enzyme (corresponding to 10 mg of Lipase PS) obtained thus was added to 1 ml of 0.5 M potassium phosphate buffer (pH 8) and 100 mg of (R), (S)-N-(2,6-dimethyl phenyl) alanine 2-chloroethyl ester was then added thereto, foUowed by shaking at 200 rpm, 35°C for 16 hrs. to allow the reaction to proceed.
  • the analysis of the reaction was performed in the same manner as in EXAMPLE 3. The analysis results are Usted in TABLE 7 below.
  • EXAMPLE 11 Optical resolution of (R ⁇ (S)-N-(Z6-dimethyl phenyl) alanine methyl ester by enzyme and isolation of (R). (S)-N-(2.6-dimethyl phenyl) alanine
  • EXAMPLE 12 Optical resolution of (K), (S)-N-(2,6-dimethyl phenyl) alanine methoxyethyl ester by enzyme and isolation of (R)-N-(2,6-dimethyl phenyl) alanine
  • (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and its ester compound being useful as precursors for enantiomericaUy enriched Metalaxyl, Benalaxyl, Furalaxyl and the like having antifungal activity, can be readily prepared in high optical purity and yield.

Abstract

The present invention provides methods for stereospecifically preparing (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and counter ester compounds thereto using enzyme, which comprises reacting an enzyme having hydrolytic activity specific to one enantiomer of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine esters ((R)-enantiomer and (S)-enantiomer) with the racemic mixture above to obtain (R)- or (S)-N-(2,6-dimethyl phenyl) alanine by optical resolution, or extracting (S)- or (R)-N-(2,6-dimethyl phenyl) alanine ester as an unreacted compound from a reaction mixture using solvent, or esterifying a certain alanine enantiomer separated by the optical resolution with alcohol to synthesize (S)- or (R)-N-(2,6-dimethyl phenyl) alanine ester.

Description

METHOD FOR PREPARING A (R)- OR (S)- FORM OF N-(2,6-DIMETHYL
PHENYL) ALANINE AND A COUNTER ENANTIOMERIC FORM OF N-(2,6-
DHVDETHYL PHENYL) ALANINE ESTER THERETO USING ENZYME
FIELD OF THE INVENTION
The present invention relates to methods for stereospecifically preparing (R)- or (S)-N-
(2,6-dimethyl phenyl) alanine and counter ester compounds thereto using enzyme, more specifically, methods of comprising reacting an enzyme having hydrolytic activity specific to one kind of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine esters ((R)-enantiomer and (S)- enantiomer) with the racemic mixture above to obtain (R)- or (S)-N-(2,6-dimethyl phenyl) alanine by optical resolution, or extracting (S)- or (R)-N-(2,6-dimethyl phenyl) alanine ester as an unreacted compound from a reaction mixture using solvent, or esterifying a certain alanine enantiomer separated by the optical resolution with alcohol to synthesize (S)- or (R)-N-(2,6- dimethyl phenyl) -danine ester.
BACKGROUNDOFTHEINVENΗON
Racemic (R), (S)-N-(2,6-dime1hyl phenyl) alanine and their ester compounds are useful as precursors for the synthesis of Metalaxyl, Benalaxyl, Furalaxyl, etc. having antifungal activity. The antifungal activity of these compounds is generally resides with the (R)- enantiomer.
Synthesis of Metalaxyl-M which is (R)-enantiomer of Metalaxyl has been reported to be achieved by hydrogenation of enamide in the presence of a chiral metallic catalyst {Pesticide
Science, Vol. 54, 1998, pp 302-304). This reaction provides Metalaxyl-M in 95.6% ee (% enantiomeric excess) but requires an expensive metallic catalyst and a releasing process such as treatment under high temperature and high pressure.
As one approach for preparation of an optically active compound, (R)- or (S)-N-(2,6- dimethyl phenyl) alanine, an optical resolution has been known employing optically pure amine as resolving agent, for example, (R)- or (S)-phenylemylamine to separate the racemic mixture (U.S. Patent No. 4,919,709). However, this method has some demerits that the above resolving agent is expensive and the process therefor is complicated.
As one approach for synthesis of (R)-N-(2,6-dimethyl phenyl) alanine methyl ester, it has been reported that a sulfonate derivative is made starting from methyl (S)-2-(hydroxy)- propanoate and then reacted with 2,6-dimethyl aniline in the presence of base (WO 00/76960). However, according to this method, it is difficult to obtain (R)-N-(2,6-dimethyl phenyl) alanine methyl ester with enantiomeric excess greater than 95% ee, and high temperature is required for performance of the process. And also (R)-N-(2,6-dimethyl phenyl) alanine methyl ester can also be applied to the chiral form of Benalaxyl, Furalaxyl, etc.; however, the required optical purity for Metalaxyl-M is more than 95% ee.
Meanwhile, for optical resolution of racemic mixtures, the use of enzymes such as esterases, Upases and proteases has been known which selectively hydrolyze enantiomers. For example, hydrolyzing racemic methyl-2-chloropropionates with lipase isolated from Candida rugosa has been reported (Biotechnology & Bioengineering 30, 1987, pp 995-999). Moreover, synthesizing (R)-2-(4-hydroxyphenoxy) propionic acid with purified Candida rugosa lipase has beenreported (WO 90/15146).
While the use of enzymes for the optical resolution of racemic mixtures is very effective, it is very difificult to determine which racemic mixtures can be applied to enzymatic resolution and which enzymes can be employed for the optical resolution of a specific racemic rnixture. For example, inventors of U.S. Patent No. 5,928,933 performed experiments for optical resolution of racemic 4-oxo-l,2-pyrrolidine dicarboxylic acid dialkyl esters using about forty-four different enzymes chosen from proteases, Upases and esterases, and found only one enzyme yielding an optical purity of 95%. Like this case, the optimal choice of enzyme and substrate is not easily predicted, but requires a careful screening of a variety of enzymes while varying the chemical structure of potential substrates.
Meanwhile, with respect to racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine of the present invention, no attempts using any enzymes for the optical resolution thereof have been made. The existing optical resolutions using enzymes have been limited to the synthesis of aryloxypropionic acid as a precursor for crop-based herbicide and the synthesis of arylpropionic acid as a precursor for profen-based antiinflamatory agent. In other words, there have not yet been any reports of using enzymes for the optical resolution of racemic (R), (S)-N-(2,6- dimethyl phenyl) alanine ester.
SUMMARY OF THE INVENTION
The inventors of the present invention have carried out extensive investigations and thereby determined that when the racemic mixture of (R), (S)-N-(2,6-dirnethyl phenyl) alanine ester is reacted under room temperature and atmospheric pressure with an enzyme hydrolysizing only one of both enantiomers in the racemic mixture, (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and its counter ester can be prepared at high optical purity (> 96-99% ee). The present invention is achieved based upon this finding.
Accordingly, the object of the present invention is to provide a method of economicaUy preparing (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester at high optical purity by optical resolution using enzyme.
According to an aspect of the present invention, the method of preparing (R)- or (S)-N- (2,6-dimethyl phenyl) alanine comprises steps of,
(A) reacting racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester as represented in Formula 1 below,
where
R is selected from the group consisting of unsubstituted or substituted and linear or branched Cι- 8 alkyl or alkenyl, unsubstituted or substituted C3-C6 cycloalkyl, unsubstituted or substituted aryl alkyl, and unsubstituted or substituted heteroaryl alkyl,
with an effective amount of an enzyme which enantioselectively hydrolyzes one enantiomeric form thereof to produce an (R)-form or (S)-form of N-(2,6-dimethyl phenyl) alanine ("(R)-form alanine" or "(S)-form alanine") and a counter enantiomeric form of N-(2,6- dimethyl phenyl) alanine ester ("counter (S)-form ester" or "counter (R)-form ester"); and
(B) isolating the (R)-form or (S)-form alanine from a reaction mixture to obtain an opticaUy pure N-(2,6-dimethyl phenyl) alanine.
R in Formula 1 includes, but is not limited to, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, 2-pentyl, 3-methyl-l-butyl, 2-ethyl-l-hexyl, 2-chloroethyl, 2- bromoethyl, 3-chloropropyl, 3-bromopropyl, 2^-dichloroethyl, l-chloro-2-propyl, oleyl, cyclohexyl, 1-cyclopropylmethyl, aUyl, phenyl, benzyl, propargyl, 2-phenoxy-l -ethyl, 2,4- dichlorobenzyl, methoxyethyl, ethoxyethyl, 1-thioethoxyethyl, and the like.
According to another aspect of the present invention, a method of preparing (R)- or (S)-
N-(2,6-dimethyl phenyl) -danine ester comprises the steps of,
(A') reacting racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester as represented in
Formula 1 above with an effective amount of an enzyme which enantioselectively hydrolyzes one enantiomeric form thereof to produce an (R)-form or (S)-form of N-(2,6-dimethyl phenyl) alanine ("(R)-form alanine" or "(S)-form alanine") and a counter enantiomeric form of N-(2,6- dimethyl phenyl) alanine ester ("counter (S)-form ester" or "counter (R)-form ester"); and
(B') isolating the unhydrolyzed counter (S)-form or (R)-form ester from a reaction mixture to obtain an optically pure N-(2,6-dimethyl phenyl) alanine ester.
In an embodiment, the step (B') may be replaced with the following step (B"):
(B") isolating the created (R)-form or (S)-form alanine from a reaction mixture and then esterifying the (R)-form or (S)-form danine with an alcohol, R-OH, wherein R is the same as in Formula 1, to produce an optically N-(2,6-dimethyl phenyl) alanine ester.
DETAILED DESCRIPTION OF THE INVENTION
Some terms and abbreviations used in this disclosure are defined as the below.
The term "racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester" is used to express the racemic n ixture of (R)-N-(2,6-dimethyl phenyl) alanine ester and (S)-N-(2,6-dimethyl phenyl) alanine ester.
The term "enantiomer" is used to express one of a pair of molecular entities which are mirror images of each other and non-superimposable. The term "enantiomer" is employed to sometimes express an enantiomeric alanine and sometimes express an enantiomeric alanine ester, depending upon contexts in this disclosure.
The term "counter" is used to express the corresponding ester of a complementary enantiomeric alanine to a certain enantiomeric alanine; i.e., the counter ester to (R)-N-(2,6- dimethyl phenyl) alanine means (S)-N-(2,6-dimethyl phenyl) alanine ester, and the counter ester to (S)-N-(2,6-dimethyl phenyl) alanine means (T)-N-(2,6-dimethyl phenyl) alanine ester.
For convenience of lustration, the term "(R)-N-(2,6-dimethyl phenyl) alanine" is sometimes abbreviated as "(R)-form alanine" and the term "(S)-N-(2,6-dimethyl phenyl) alanine" is sometimes abbreviated as "(S)-form alanine." Likewise, the term "(R)-N-(2,6- dimethyl phenyl) alanine ester" is sometimes abbreviated as "(R)-form ester" and the term "(S)- N-(2,6-dimethyl phenyl) alanine ester" is sometimes abbreviated as "(S)-form ester." In some cases, the term "(R)-form enantiomer" or "(S)-form enantiomer" is used and its meaning, i.e., whether it is used to express (R)-form alanine or (R)-form alanine ester, can be easily understood in the related contexts.
Methods for preparing racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester, to which the optical resolution is carried out according to the present invention, are well known in the art to which the present invention pertains. As one example, the racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester can be readily synthesized by reaction of 2-bromopropionic acid ester and 2,6-dimethylaniline. However, it is very difficult to isolate only (R)-form enantiomer or (S)- form enantiomer from the racemic mixture of (R), (S)-N-(2,6-dimethyl phenyl) alanine ester because both enantiomers have very similar physical and chemical properties.
Therefore, relative to previously known methods for optical resolution by chemical synthesis or separation, the present invention uses an enzyme which enantioselectively hydrolyzes only one of (R)-form enantiomer [(R)-N-(2,6-dimethyl phenyl) alanine ester] and (S)-form enantiomer [(S)-N-(2,6-dimethyl phenyl) alanine ester] (hereinafter, sometimes referred to as "specific hydrolysis enzyme"), thereby allowing a particular enantiomer to be readily synthesized by a simple and inexpensive process.
In the step (A) of the method for preparation of (R)- or (S)-N-(2,6-dimethyl phenyl) alanine, the racemic ester mixture is dissolved in an aqueous solution or a mixed solution consisting of water and a small amount of organic solvent and then reacted with a specific hydrolysis enzyme at a uniform temperature and pH.
Where a specific hydrolysis enzyme enantioselectively hydrolyzes (R)-form enantiomer, only (R)-form ester is hydrolyzed in the reaction of the step (A) such that (R)-N- (2,6-dimethyl phenyl) alanine is created and (S)-form ester, i.e., (S)-N-(2,6-dimethyl phenyl) danine ester remains unreacted. Conversely, where a specific hydrolysis enzyme enantioselectively hydrolyzes (S)-form enantiomer, only (S)-form ester is hydrolyzed in the reaction of the step (A) such that (S)-N-(2,6-dimethyl phenyl) alanine is created and (R)-form ester, i.e., (R)-N-(2,6-dimethyl phenyl) alanine ester remains unreacted.
Isolation of the hydrolyzed enantiomer from the reaction mixture in the step (B) can be achieved in different ways, depending upon a reaction system. Where the reaction system consists of only aqueous solution, an unhydrolyzed ester compound ((R)- or (S)-form ester) can be extracted using organic solvents. Where the reaction system consists of a mixed solution of organic solvent and aqueous solution, an organic layer containing an unhydrolyzed ester compound can be readily partitioned to obtain an aqueous layer containing newly synthesized alanine because the unhydrolyzed ester compound tends to be soluble in organic solvents.
(R)- or (S)-form alanine which is contained in the aqueous solution or in the aqueous layer is acidified and then extracted using an organic solvent, whereafter the organic solvent is removed to obtain the optically pure (R)- or (S)-N-(2,6-dimethyl phenyl) alanine. From various experiments, (R)- or (S)-N-(2,6-dimethyl phenyl) alanine obtained by the methods according to the present invention was ascertained to have a very high optical purity (> 96 - 99% ee).
Likewise, (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester was also ascertained to have a very high optical purity (> 96 - 99% ee), which was separated in the unreacted form from the reaction mixture in the step (B'), or synthesized by esterification of the synthesized (R)- or (S)-N-(2,6-dimethyl phenyl) alanine with the alcohol in the step (B").
R in Formula 1 is desirably selected from the group consisting of allyl, 2-chloroethyl, melhoxyethyl and ethoxyethyl because these groups can aUow a short reaction time and increased optical purity.
The kinds of specific hydrolysis enzymes are not particularly limited so long as they can enantioselectively hydrolyze only one of (R)-form ester and (S)-form ester, but are preferably selected from Upases, proteases and esterases derived from microorganisms, animals or plants.
Among them, Upases are preferable, providing a high enantioselectivity and good optical purity. More preferably, the specific hydrolysis enzyme is one or more selected from the group consisting of Lipase AK from Pseudomonas, Toyobo Immobilized lipase, Lipoprotein
Upase, Lipase PS and AH from Burkhoderia, Lipase QLM from Alcaligenes, and Lipase OF from Candida, which are particularly good in view of their enantioselectivity and reaction rate.
Selectivity to (R)-form and (S)-form enantiomers is determined by the kind of enzymes used in the hydrolysis reaction. Enzyme may be applied to the reaction system in the form of powder or aqueous solution. In some embodiments, a support-immobilized enzyme can be employed to simptify catalyst recovery for reuse. Such immobilization methods, e.g., attaching enzymes onto polymer support or inorganic support such as ceUte, are well known to those skilled in the art, and the detailed description thereof is therefore omitted.
Since the effective amount of enzyme depends upon the reaction parameters, for example, the reaction temperature, pH, concentration, reaction time, etc., its addition amount may be variably determined. In some embodiments, the effective amount of enzyme is preferably in the range of 0.1 - 100% by weight based upon the weight of substrate (racemic ester mixture). If the amount of enzyme used in the reaction is below the rninimum effective amount, the reaction time may be undesirably extended, and if the amount of enzyme is above a certain maximum effective value, the cost of the process is undesirably increased by the use of excessive enzyme and more extensive separation processes.
The reaction conditions are not particularly limited but, for optimization of the enzymatic reaction, are preferably in the range of pH 3 - 12 and temperature 0 - 60°C, more preferably 30 - 50°C. As mentioned above, the hydrolysis reaction of step (A) may be carried out in an aqueous solution, or a mixed solution containing a small amount of organic solvent so as to enhance the solubility of substrate and reduce the inhibition of enzyme activity by reaction products.
The concentration of substrate used in the enzymatic reaction may also be varied depending upon various reaction parameters. Preferably, it is in the range of 500 mM - 1M for optimization of the enzymatic reaction but may be beyond 1 M in some cases. In the hydrolysis of step (A) and (A'), ester compounds of the racemic mixture may not be weU dissolved in an aqueous solution described in the initial procedure, but some ester compounds dissolved in the aqueous solution contact and react with the enzyme. In order to increase the reaction rate and maintain the activity of enzyme, a reaction system consisting of a smaU amount of water and a large amount of organic solvent may be used.
Examples of the organic solvent used in the enzymatic reaction include, but are not limited to, hydrophilic solvents such as acetone, acetonitrile, alcohol, etc. and hydrophobic solvents such as isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc. In some embodiments, a two-phase solvent consisting of hydrophiUc and hydrophobic solvents can also be employed.
Examples of the organic solvent used in the extraction of step (B) or (B') include, but are not limited to, ethyl acetate, isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc. and the mixture of two or more thereof.
The esterification reaction in the step (B") is not particularly limited so long as it can be accomplished by reaction between the carboxyl group of (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and alcohol to give the desired (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester, which can be easily achieved by those skilled in the art, thus the description thereof is omitted in this disclosure.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Hereinafter, the present invention will be described in more detail by EXAMPLES, but the scope of the present invention is not limited thereto.
EXAMPLE 1 : Enzyme screens for optical resolution of racemic (R\ (S>N-(2,6-dimethyl phenyl1) alanine methyl ester
A substrate solution containing 50 μl of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine methyl ester in 500 μl of acetonitrile was added to 450 μl of potassium phosphate buffer and 25 mg of enzyme powder (in the case of enzyme solution, corresponding to 20 μl of enzyme solution) was then added thereto. Reactions were run at 30°C for 1 and 2 days. The conversion rate of reaction was analyzed by HPLC on a C18 reverse phase column with a mixture of acetonitrile and water (acetonitrile : water = 70 : 30, 0.1% trifluoroacetic acid) as the eluting solvent while detecting at 254 nm wavelength. The kinds of enzymes used and the conversion rates of the racemic mixture are Usted in TABLE 1 below.
TABLE 1
In TABLE 1 above, enzymes showing a conversion rate of around 50% after the lapse of a certain reaction time are potential candidates as highly enantioselective enzymes specific to (R)-form enantiomer or (S)-form enantiomer. In this view, a variety of Upases can be considered as such candidates having a high enantioselectivity.
EXAMPLE 2: Enzyme screens for optical resolution of racemic (R . ("S -N-("2,6-dimethyl phenyl") alanine methyl ester
A racemic mixture of enriched (chemical synthesized) (R)-N-(2,6-dimethyl phenyl) alanine methyl ester (R : S = 90 : 10) and a racemic n-iixture of enriched (chemical synthesized) (S)-N-(2,6-dimethyl phenyl) alanine methyl ester (R : S = 4 : 96) were prepared respectively, and the conversions rates were measured in the same manner as in EXAMPLE 1. The kinds of enzymes used in experiment and the conversion rates of the racemic mixtures are Usted in TABLE 2 below.
TABLE 2
From the results in TABLE 2 above, it can be seen that Lipase AK, PS and QLM have high enantioselectivity specific to (R)-form enantiomer.
EXAMPLE 3: Enzyme screens for optical resolution of racemic (R\ (S -N-("2.6-dimethyl phenyl) alanine aUyl ester and racemic (R ("S -N-(2.6-dimethyl phenvD alanine 2-chloroethyl ester
2 mg of enzyme powder was suspended in 1 ml of 0.1 M potassium phosphate buffer (pH 7.0) and 20 mg of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine aUyl ester was then added thereto, followed by shaking of the resulting mixture at 200 rpm and 35°C. After 3 and 24 hours, respectively, 20 μ of sample was dissolved in a mixed solution of hexane and isopropyl alcohol (hexane : isopropyl alcohol = 95 : 5) and adjusted to pH 10 using 5% Na2CO3. The unreacted ester compound was extracted to the organic layer (organic solvent). The aqueous layer was adjusted to pH 3 - 4 using 1 N HC1, then was extracted with ethyl acetate. After partitioning the layers, organic solvents were removed by vacuum distillation and the residue was again dissolved in a mixed solution of hexane and isopropyl alcohol (hexane : isopropyl alcohol = 95 : 5) to analyze the enantioselectivity.
The above procedure was repeated in the same manner except for using (R), (S)-N- (2,6-dimethyl phenyl) alanine 2-chloroethyl ester instead of the above racemic (R), (S)-N-(2,6- dimethyl phenyl) alanine allyl ester.
The analysis conditions are the foUowing:
Chiracel OD column, 30°C, 0.8 ml, 254 nm
Acid analysis - hexane : isopropyl alcohol : trifluoroacetic acid = 95 : 5 : 0.1 Ester analysis - hexane : isopropyl alcohol = 100 : 1
The analysis results are Usted in TABLE 3 below.
TABLE 3
conv. = e&j / (ees + ee,,)
wherein conv. means conversion, and eep and e^ mean the optical purity of product and the optical purity of reactant, respectively, as represented by the below formulas.
ees = [(R)-N-(2,6-dimethyl phenyl) alanine ester - (S)-N-(2,6-dimethyl phenyl) alanine ester] / [(R)-N-(2,6-dimethyl phenyl) alanine ester + (S)-N-(2,6-dimethyl phenyl) alanine ester]
eep = [(R)-N-(2,6-dimethyl phenyl) alanine - (S)-N-(2,6-dimethyl phenyl) alanine] / [(R)-N- (2,6-dimethyl phenyl) alanine + (S)-N-(2,6-dimethyl phenyl) alanine]
As can be seen in TABLE 3, some Upases have a high conversion rate of around 50% and good enantioselectivity in both the racemic mixture of allyl ester and the racemic mixture of 2-chloroethyl ester, and the optimal reaction times vary depending upon the kind of esters.
EXAMPLE 4: Optical resolution of (R fSVN-(Z6-dimethyl phenyl) alanine 2-chloroethyl ester by Lipase OF 20 mg of a racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine 2-chloroethyl ester was added to 1 ml of 1 M potassium phosphate buffer (pH 7.0) and 2 mg of Lipase OF was then added thereto, foUowed by shaking of the resulting mixture at 200 rpm and 35°C. The analysis of reaction was carried out in the same manner as in EXAMPLE 3. After 17 hrs, (S)-N-(2,6- dimethyl phenyl) alanine of 70.8% ee was obtained at 41.4% conversion. Since Candida rugosa Lipase OF comprises mixed forms of a variety of isozymes, use of a specific isozyme among them is anticipated to be able to increase the optical purity of product.
EXAMPLE 5: Reactivity of enzyme depending upon the kind of esters
20 mg of a variety of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine esters were dissolved in 1 ml of 0.1 M potassium phosphate buffer (pH 7.0), respectively, and 2 mg of Lipase PS was added thereto, then the analysis was performed in the same manner as in EXAMPLE 3. The analysis results are Usted in TABLE 4 below.
TABLE 4
Conv. = ees/(ees + eep)
As can be seen in TABLE 4 above, 2-chloroethyl, 2-bromoethyl, allyl, methoxyethyl, ethoxyethyl ester and the like are particularly preferable as substrates for Lipase PS.
EXAMPLE 6: Optical resolution of racemic (R), (S -N-(2,6-dimethyl phenyl) alanine 2- chloroethyl ester
500 mg of a racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine 2-chloroethyl ester was added to 2.5 ml of potassium phosphate buffer (pH 7.0) (concentration: 200 g/1) and 10 mg of enzyme was then added thereto (ester : enzyme = 50 : 1), foUowed by shaking the resulting mixture at 200 rpm and 35°C. The analysis of reaction was performed in the same manner as in EXAMPLE 3. The analysis results are Usted in TABLE 5 below.
TABLE 5
Conv. = ees (ees + eep)
The results of TABLE 5 above show that the above-referenced racemate can be enantioselectively separated by the enzymes listed therein at an exceUent conversion rate and optical purity. Furthermore, Lipase AK, PS and QLM provide a very high conversion rate approaching 50%.
EXAMPLE 7: Optical resolution of racemic (R , (SVN-(2,6-dimethyl phenvD alanine ester varies with ratio of substrate and enzyme
1 g of several racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine esters was added to 2.5 ml of 0.5 M potassium phosphate buffer (pH 7) (concentration: 400 g/L) and varying amounts of enzyme were then added thereto, respectively, foUowed by shaking the resulting niixture at
200 rpm and 35°C. The analysis of the reaction was carried out in the same manner as in
EXAMPLE 3. The analysis results are Usted in TABLE 6 below.
TABLE 6
Conv. = ee<J ees + eep)
As seen in TABLE 6 above, it can be seen that the conversion rate increases as the amount of enzyme used increases. It can also be seen that the optimal amount of enzyme should be determined considering various parameters such as the kinds of enzyme and ester, conversion rate, optical purity and the like.
EXAMPLE 8: Optical resolution of racemic (R), (S -N-(2,6-dimethyl phenyl) alanine methyl ester by immobilized Lipase PS
0.1 g of Lipase PS was dissolved in 10 ml of 0.1 M calcium phosphate buffer (pH 7.0) and the resulting mixture was maintained at room temperature with being stirred, followed by filtering to remove insoluble materials. 4.5 ml of the filtrate solution was mixed with 1 M potassium phosphate (pH 7.0) and 30 mg of Sepabeads FP-EP16® (Resindion) was then added thereto, foUowed by stirring at room temperature overnight and subsequent filtering. The bead- immobilized enzyme obtained thus was added to 1 ml of 0.1 M Tris buffer (pH 7), 10 mg of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine methyl ester was added thereto, then the reaction was run at 30°C for 17 hours while being shaken at 200 rpm. The analysis of reaction was performed at the same manner as in EXAMPLE 3.
The above procedure was repeated except for using Eupergit C® (Rohm & Haas) as a support for enzyme immobilization.
In the case of Sepabeads FP-EP16®, (R)-N-(2,6-dimethyl phenyl) alanine of 98.5% ee was obtained at 25% conversion. In the case of Eupergit C®, (R)-N-(2,6-dimethyl phenyl) alanine of 98.4% ee was obtained at 46% conversion.
EXAMPLE 9: Optical resolution of (R\ fSVN-f2.6-dJmethyl phenyl) alanine 2-chloroethyl ester by immobilized Lipase PS
0.1 g of Lipase PS was dissolved in 5.0 ml of 0.1 M sodium phosphate buffer (pH 6.0) and, while being stirred, XAD®-7HP (Rohm & Haas) was added thereto at varying amounts of 100 mg (resin : enzyme = 1 : 1), 250 mg, 500 mg and 1.0 g. The resulting mixture was stirred at 30°C for 24 hours and then filtered. The resin and insoluble materials were added to 0.1 M sodium phosphate buffer (pH 6.0) and 5 μl of glutaraldehyde was also added thereto, foUowed by stirring at room temperature for 3 hrs. The immobilized enzyme (corresponding to 10 mg of Lipase PS) obtained thus was added to 1 ml of 0.5 M potassium phosphate buffer (pH 8) and 100 mg of (R), (S)-N-(2,6-dimethyl phenyl) alanine 2-chloroethyl ester was then added thereto, foUowed by shaking at 200 rpm, 35°C for 16 hrs. to allow the reaction to proceed. The analysis of the reaction was performed in the same manner as in EXAMPLE 3. The analysis results are Usted in TABLE 7 below.
TABLE 7
Conv. = ees/(ees + eep)
EXAMPLE 10: Optical resolution of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine methyl ester in mass production
20 ml of (R), (S)-N-(2,6-dimethyl phenyl) alanine methyl ester (concentration: 400 g L) was added to 30 ml of distiUed water and 500 mg of Lipase PS was then added thereto, followed by stirring (30%, Mettler DL70 titrator) at 40°C to run a reaction. In order to maintain uniform pH of the reaction mixture, 1 N NaOH was automaticaUy added thereto (Mettler DL70 titrator). After 24 hrs, 250 mg of Lipase PS was additionaUy added thereto. The analysis of the reaction was carried out in the same manner as in EXAMPLE 3. (R)-N-(2,6-dimethyl phenyl) alanine of 96.9% ee was obtained at 40.2% conversion (after 6 days).
EXAMPLE 11: Optical resolution of (R\ (S)-N-(Z6-dimethyl phenyl) alanine methyl ester by enzyme and isolation of (R). (S)-N-(2.6-dimethyl phenyl) alanine
A reaction solution of EXAMPLE 9 was filtered to remove insoluble materials, then the resulting filtrate was passed through a glass column in which 2.72 g of Accurel MPIOOO was fiUed, wherein the Accurel MPIOOO had been equilibrated with methanol and distiUed water. Ethyl acetate was added to the filtrate passed thus and pH was adjusted to 9, then the layer of ethyl acetate was analyzed by chiral HPLC to obtain the result of (S)-ester : (R)-ester = 95.6 : 1.1 (area % ratio) and ester : acid = 96.7 : 0.87 (area % ratio). In addition, the aqueous layer was acidified to extract with ethyl acetate and the solvent was evaporated, then analysis was performed by chiral HPLC to ascertain that a white (R)-N-(2,6-dimethyl phenyl) alanine was quantitatively obtained at the optical purity of (R)-acid of 97.2% ee and ester : acid = 0.42 : 99.58 (area % ratio).
EXAMPLE 12: Optical resolution of (K), (S)-N-(2,6-dimethyl phenyl) alanine methoxyethyl ester by enzyme and isolation of (R)-N-(2,6-dimethyl phenyl) alanine
24 g of racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine methoxyethyl ester was added to 50 ml of 0.5 M potassium phosphate buffer (pH 7.0) and 1.0 g of Lipase PS was then added thereto, followed by shaking at 200 rpm and 35°C to run a reaction. After the reaction was stopped at 40% conversion, ethyl acetate was added and pH of the aqueous layer was adjusted to 10, then the ethyl acetate layer was partitioned and water was added thereto. The aqueous layer was adjusted to pH 3 - 4, and the ethyl acetate layer was dried over MgSO and then filtered. When ethyl acetate was evaporated, 5.3 g of (R)-N-(2,6-dimethyl phenyl) alanine was obtained at a yield of 57.4%, of which the optical purity was 96% ee when measured by chiral HPLC analysis.
EXAMPLE 13: Esterification of (RVN-(2.6-dimethyl phenyl) alanine
5.03 g of (R)-N-(2,6-dimethyl phenyl) alanine (96% ee) was dissolved in 15 g of methanol, then 3.25 g (1.05 equivalent) of thionyl chloride was added dropwise thereto at 0°C. After reflux for 2 hrs, when GC analysis was performed, it was ascertained that 2.5% of the (R)- N-(2,6-dimethyl phenyl) alanine remained. Solvent was evaporated and 30 ml of toluene was then added, followed by washing with 50 ml of Na2CO3 5 times. The toluene layer was partitioned, foUowed by drying over MgSO4 to remove the solvent. When (R)-N-(2,6-dimethyl phenyl) alanine methyl ester (4.2 g; isolated yield: 78%) obtained thus was analyzed by chiral HPLC, the optical purity was 97.3% ee. When measured by GC analysis, the chemical purity was 97.2%.
INDUSTRIAL APPLICABILITY
As described above, according to the methods of the present invention, a racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester which cannot be enantioselectively resolved by previously known methods because of similar chemical and physical properties can be separated to obtain R-form enantiomer and S-form enantiomer in a simple and low cost process. Accordingly, by the methods of the present invention, (R)- or (S)-N-(2,6-dimethyl phenyl) alanine and its ester compound, being useful as precursors for enantiomericaUy enriched Metalaxyl, Benalaxyl, Furalaxyl and the like having antifungal activity, can be readily prepared in high optical purity and yield.
As the present invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, it should also be understood that the above-described examples are not limited by any of the detaUs of the foregoing description, unless otherwise specified, but rather should be construed broadly within its spirit and scope as defined in the appended claims, and therefore aU changes and modifications that faU within the meets and bounds of the claims, or equivalences of such meets and bounds are therefore intended to be embraced by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A method of preparing (R)- or (S)-N-(2,6-dimethyl phenyl) alanine comprising the steps of,
(A) reacting racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester as represented in Formula 1 below,
where
R is selected from the group consisting of unsubstituted or substituted and linear or branched Cι-Cι8 alkyl or alkenyl, unsubstituted or substituted C3-C6 cycloalkyl, unsubstituted or substituted aryl alkyl, and unsubstituted or substituted heteroaryl alkyl,
with an effective amount of an enzyme which enantioselectively hydrolyzes one enantiomeric form thereof to produce an (R)-form or (S)-form of N-(2,6-dimethyl phenyl) alanine ("(R)-form alanine" or "(S)-form alanine") and a counter enantiomeric form of N-(2,6- dimethyl phenyl) alanine ester ("counter (S)-form ester" or "counter (R)-form ester"); and
(B) isolating the synthesized (R)-form or (S)-form alanine from a reaction mixture to obtain an opticaUy pure N-(2,6-dimethyl phenyl) alanine.
2. A method of preparing (R)- or (S)-N-(2,6-dimethyl phenyl) alanine ester comprising the steps of,
(A') reacting racemic (R), (S)-N-(2,6-dimethyl phenyl) alanine ester as represented in
Formula 1 above with an effective amount of an enzyme which enantioselectively hydrolyzes one enantiomeric form thereof to produce an (R)-form or (S)-form of N-(2,6-dimethyl phenyl) alanine ("(R)-form alanine" or "(S)-form alanine") and a counter enantiomeric form of N-(2,6- dimethyl phenyl) alanine ester ("counter (S)-form ester" or "counter (R)-form ester"); and
(B') isolating the unhydrolyzed counter (S)-form or (R)-form ester from a reaction mixture to obtain an optically pure N-(2,6-dimethyl phenyl) alanine ester.
3. The method of claim 2, wherein the step (B') is replaced with the following step (B"):
(B") isolating the synthesized (R)-form or (S)-form danine from a reaction mixture and then esterifying the (R)-form or (S)-form alanine with an alcohol, R-OH, wherein R is the same as in Formula 1, to produce an opticaUy pure N-(2,6-dimethyl phenyl) alanine ester.
4. The method of claim 1, wherein R is selected from the group consisting of allyl, 2- chloroethyl, methoxyethyl and ethoxyethyl.
5. The method of claim 1 or 2, wherein the enzyme is one or more selected from Upases, proteases and esterases derived from microorganisms, animals or plants.
6. The method of claim 5, wherein the enzyme is Upase.
7. The method of claim 5, wherein the enzyme is one or more selected from the group of Lipase AK from Pseudomonas, Toyobo Immobilized Upase, Lipoprotein lipase, Lipase PS and AH from Burkhoderia, Lipase QLM from Alcaligenes, and Lipase OF from Candida.
8. The method of claim 1 or 2, wherein a hydrolysis reaction by the enzyme is carried out in an aqueous solution, or a mixed solution containing a smaU amount of organic solvent.
9. The method of claim 8, wherein the organic solvent is a hydrophilic solvent such as acetone, acetonitrile, alcohol, etc. or a hydrophobic solvent such as isopropyl ether, tert-butyl methyl ether, chloroform, dichloromethane, carbon tetrachloride, hexane, toluene, etc., or mixtures thereof.
10. The method of claim 1 or 2, wherein the hydrolysis reaction is performed at pH 3 - 12 and O-60°C.
11. The method of claim 1 or 2, wherein the isolation is achieved by extracting an unhydrolyzed ester compound ((R)- or (S)-form ester) using organic solvent in the case of the reaction system of only aqueous solution, and partitioning an organic layer containing an unhydrolyzed ester compound to obtain an aqueous layer contairiing a synthesized enantiomeric alanine in the case of the reaction system of a mixed solution of organic solvent and aqueous solution.
12. The method of claim 1 or 2, wherein the enzyme is an immobilized enzyme on supports or enzyme aggregates crosslinked in any form.
EP03813309A 2002-12-18 2003-12-05 Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme Withdrawn EP1587943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020020081152A KR100654587B1 (en) 2002-12-18 2002-12-18 Method for preparing an R- or S- form of N-2,6-dimethyl phenyl alanine and a counter enantiomeric form of N-2,6-dimethyl phenyl alanine ester thereto using enzyme
KR2002081152 2002-12-18
PCT/KR2003/002673 WO2004055195A1 (en) 2002-12-18 2003-12-05 Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme

Publications (1)

Publication Number Publication Date
EP1587943A1 true EP1587943A1 (en) 2005-10-26

Family

ID=36165444

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813309A Withdrawn EP1587943A1 (en) 2002-12-18 2003-12-05 Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme

Country Status (5)

Country Link
EP (1) EP1587943A1 (en)
JP (1) JP2006510364A (en)
KR (1) KR100654587B1 (en)
AU (1) AU2003303073A1 (en)
WO (1) WO2004055195A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5010266B2 (en) * 2006-01-17 2012-08-29 住友化学株式会社 Process for producing optically active biphenylalanine compound or salt thereof and ester thereof
US8017378B2 (en) 2006-01-17 2011-09-13 Sumitomo Chemical Company, Limited Method for production of optically active biphenylalanine compound or salt or ester thereof
KR101370414B1 (en) * 2012-09-28 2014-03-06 린나이코리아 주식회사 System and method for detection of cutting off water into steam oven by temperature measurement of drain
EP3061753B1 (en) 2015-02-27 2018-08-22 Universita' Degli Studi "G. d'Annunzio" Chieti-Pescara Enantio-selective synthesis of non-natural amino acids
WO2017155025A1 (en) * 2016-03-10 2017-09-14 第一三共株式会社 Method for producing optically active valeric acid derivatives using optical resolution by enzyme
CN106119163A (en) * 2016-06-29 2016-11-16 浙江工业大学 Bacillus albus zjut528 and the application in splitting metalaxyl
CN107446960A (en) * 2017-09-30 2017-12-08 湖南理工学院 A kind of method that 2,3 diphenyl-propionic acid enantiomers are split using biological enzyme stereoselectivity
CN111607631B (en) * 2020-07-06 2022-09-30 浙江工业大学 Enzymatic synthesis method of (S) -o-chlorophenylglycine methyl ester
CN112195170B (en) * 2020-07-15 2023-01-10 浙江工业大学 Immobilized recombinant esterase and application thereof in preparing R-2, 6-dimethylphenyl aminopropionic acid
CN112899337B (en) * 2021-01-26 2022-12-20 普洛药业股份有限公司 Method for preparing D-p-methylsulfonylphenylserine ethyl ester under catalysis of immobilized enzyme

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115470B1 (en) * 1983-01-25 1986-12-17 Ciba-Geigy Ag Optically active n-(1'-methyl-2'-methoxymethyl)-n-chloracetyl-2,6-dimethylaniline as herbicide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004055195A1 *

Also Published As

Publication number Publication date
JP2006510364A (en) 2006-03-30
WO2004055195A1 (en) 2004-07-01
AU2003303073A1 (en) 2004-07-09
KR100654587B1 (en) 2006-12-07
KR20040054842A (en) 2004-06-26

Similar Documents

Publication Publication Date Title
US5728876A (en) Resolution of the racemates of primary and secondary amines by enzyme-catalyzed acylation
JP3789938B2 (en) Racemic resolution of primary and secondary heteroatom-substituted amines by enzyme-catalyzed acylation
EP0288994A2 (en) Process for producing optically active compounds
WO2004055195A1 (en) Method for preparing a (r)- or (s)- form of n-(2,6-dimethyl phenyl) alanine and a counter enantiomeric form of n-(2,6-dimethyl phenyl) alanine ester thereto using enzyme
IL170310A (en) Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol
US6261830B1 (en) Enzymatic process for stereoselective preparation of a tertiary acid
US6063615A (en) Enzymatic acylation of amino acid esters using a carboxylic acid ester substituted with oxygen on the alpha carbon
JP4843813B2 (en) Method for preparing R- or S-form α-substituted heterocyclic carboxylic acid and enantiomer of α-substituted heterocyclic carboxylic acid ester of the opposite mirror image using enzyme
US6187582B1 (en) Process for producing optically active amines
US4863859A (en) Process for preparing optically active glycerol derivatives
KR100650797B1 (en) Process for preparing chiral substituted cyclopropane carboxamide
EP0474250A2 (en) Enzymatic process for separating the optical isomers of racemic 1,2-diols
US7067291B2 (en) Biocatalytic preparation of enantiomerically enriched aminopentanenitrile
KR100419595B1 (en) Racemate Separation of Primary and Secondary Heteroatom-Substituted Amine by Enzyme-Catalysed Acylation
US20040209931A1 (en) Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
JP2003534807A (en) Optical resolution of racemic α-substituted heterocyclic carboxylic acids using enzymes
US8008062B2 (en) Production of (R)- and (S)-4-(1-aminoethyl) benzoic acid methyl ester sulfate by lipase acylation of racemic 4-(1-aminoethyl) benzoic acid methyl ester and sulfuric acid precipitation
JP2612671B2 (en) Method for producing optically active propionate
EP0239122A2 (en) Process for the enzymatic resolution of racemic 2-amino-1-alkanols
US7326559B2 (en) Process for preparation of optically active allenes
WO2006009338A1 (en) Process for preparing chiral substituted carboxylic acid
JP3555480B2 (en) Production method of optically active compound
JPH1146793A (en) Production of optically active glycidol
MXPA98007922A (en) Enzimative process for the stereoselective preparation of amidas terapeuti
JPH10248592A (en) Production of optically active 2-benzylsuccinic acid and its derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070703